Evercore ISI initiated coverage of Beam Therapeutics (BEAM) with an Outperform rating and $35 price target BEAM-302 offers “a potentially game-changing approach for AATD,” with early data showing impressive levels of corrected AAT production, says the analyst, who calls upcoming data due in Q1 of 2026 “crucial.”
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BEAM:
- Cathie Wood Cuts Stake in Pinterest Stock (PINS), Loads Up on Bitmine (BMNR) and Biotech Stocks
- Beam Therapeutics’ BEAM-101: Advancements in Sickle Cell Disease Therapy and Manufacturing Efficiency Drive Buy Rating
- FDA appoints Richard Pazdur as Director of CDER
- Beam Therapeutics: Promising Gene Editing Advances Justify Buy Rating
- Cathie Wood Sells Tesla (TSLA) Stock, and Buys This Stock after Q3 Beat